Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
34.17
+0.36 (1.08%)
Market open: Aug 12, 2026, 1:50 PM EDT
33.86
+0.06 (0.18%)
Previous after-hours: Aug 11, 2026, 7:59 PM EDT
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Brian Lian Ph.D. | President, CEO & Director |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer |
| Dr. Hubert C. Chen M.D., M.P.H. | Chief Medical Officer |
| Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gregory S. Zante CPA | Chief Financial Officer |
| Mr. Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing & Sales |
| Mr. Michael Morneau | Vice President of Finance & Administration |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
| Ms. Katherine Mercier | Vice President of Quality & Compliance |
| Ms. Marianne Mancini | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-07-30 | S-3ASR | vktx-20260730.htm |
| 2026-07-29 | 10-Q | vktx-20260630.htm |
| 2026-05-26 | 8-K | vktx-20260519.htm |
| 2026-04-30 | 10-Q | vktx-20260331.htm |
| 2026-04-29 | 8-K | vktx-20260429.htm |
| 2026-04-01 | DEFA14A | vktx-2026-04-01-defa14a_.htm |
| 2026-04-01 | DEF 14A | vktx-20260401.htm |
| 2026-04-01 | ARS | vktx-2026-04-01-ars.pdf |
| 2026-02-11 | 8-K | vktx-20260211.htm |
| 2026-02-11 | 10-K | vktx-20251231.htm |